CNBC June 10, 2024
Ashley Capoot

Key Points

– Abbott on Monday announced it has received FDA clearance for two new CGMs that will be available without a prescription.

– A CGM is a small sensor that pokes through the skin and tracks a person’s glucose levels in real-time. The tech is primarily used by patients with diabetes.

– Abbott’s new Libre Rio system is for patients with Type 2 diabetes that do not take insulin, while Lingo is designed for use by consumers that are trying to improve their health and wellness.

Abbott Laboratories announced Monday it received approval from the U.S. Food and Drug Administration for two new continuous glucose monitoring systems, including one for people who don’t have diabetes. Both will be available...

Today's Sponsors


Today's Sponsor


Topics: Digital Health, FDA, Govt Agencies, Medical Devices, Technology, Wearables
Pfizer, Valneva inch closer to FDA approval of 1st Lyme disease vaccine
FDA Clears Emerging Brain PET System
STAT+: Applesauce lead contamination could not have been prevented, top FDA official suggests
Trump’s FDA commissioner on regulating AI
FDA creates communication ‘super office’ at CDRH

Share This Article